Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.40 |
| ▸ | CYP21A2 | P08686 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erbulozole SCHEMBL3824 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| Erbulozole SCHEMBL9488172 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| Erbulozole SCHEMBL27849451 | 0.99 | CYP3A4 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9488205 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9488211 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9490358 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9489826 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9488791 | 0.92 | TBXAS1 (0.43) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9490323 | 0.92 | CYP3A4 (0.39) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 | |
| SCHEMBL9488796 | 0.92 | TBXAS1 (0.43) | CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| US-5236944-A | C1-4 alkyl(4-(2-(4-C1-4-alkylphenyl)-2(1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylemthlthio)phenyl)carbamate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-08-17 | — | — | US | claimed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12622910-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-12 | — | — | US | disclosed |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12617845-B2 | SMC1A antibodies and uses thereof | CITY OF HOPE (US) | 2026-05-05 | — | — | US | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-02-17 | — | — | US | disclosed |
| EP-3953372-A2 | CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS | The Regents of The University of California (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2022023772-A1 | ANTAGONIST COMPOUNDS | AdoRx Therapeutics Limited (GB) | 2022-02-03 | — | — | WO | disclosed |
| CN-215643385-U | Device for direct drug infusion | 基因泰克股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-5236944-A | C1-4 alkyl(4-(2-(4-C1-4-alkylphenyl)-2(1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylemthlthio)phenyl)carbamate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622910-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | BCL6B, BCL9, BTK | CYP3A4 3235/4885CYP19A1 3807/4885CYP17A1 2671/4885 |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CD47, IGLV6-57, STING1 | CYP3A4 4802/4885CYP19A1 3753/4885CYP17A1 4407/4885 |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | CYP3A4 2439/4885CYP19A1 3299/4885CYP17A1 4549/4885 |
| US-12617845-B2 | SMC1A antibodies and uses thereof | SMC1A, SMCHD1, SMC2 | CYP3A4 3869/4885CYP19A1 2410/4885CYP17A1 1547/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | CYP3A4 4735/4885CYP19A1 3711/4885CYP17A1 4019/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CYP3A4 4515/4885CYP19A1 4137/4885CYP17A1 4442/4885 |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | CYP3A4 4433/4885CYP19A1 3983/4885CYP17A1 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.